JPWO2021247856A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021247856A5 JPWO2021247856A5 JP2022574196A JP2022574196A JPWO2021247856A5 JP WO2021247856 A5 JPWO2021247856 A5 JP WO2021247856A5 JP 2022574196 A JP2022574196 A JP 2022574196A JP 2022574196 A JP2022574196 A JP 2022574196A JP WO2021247856 A5 JPWO2021247856 A5 JP WO2021247856A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- exon
- hematopoietic stem
- lineage
- genetically engineered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063033966P | 2020-06-03 | 2020-06-03 | |
| US202063033970P | 2020-06-03 | 2020-06-03 | |
| US63/033,970 | 2020-06-03 | ||
| US63/033,966 | 2020-06-03 | ||
| US202163183791P | 2021-05-04 | 2021-05-04 | |
| US63/183,791 | 2021-05-04 | ||
| PCT/US2021/035691 WO2021247856A2 (en) | 2020-06-03 | 2021-06-03 | Compositions and methods for inhibition of lineage specific antigens using crispr-based base editor systems |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023528415A JP2023528415A (ja) | 2023-07-04 |
| JPWO2021247856A5 true JPWO2021247856A5 (https=) | 2024-06-10 |
| JP2023528415A5 JP2023528415A5 (https=) | 2024-06-10 |
Family
ID=78831734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574196A Pending JP2023528415A (ja) | 2020-06-03 | 2021-06-03 | Ｃｒｉｓｐｒベースの塩基エディターシステムを使用した系列特異的抗原の阻害のための組成物及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240041923A1 (https=) |
| EP (1) | EP4161535A4 (https=) |
| JP (1) | JP2023528415A (https=) |
| KR (1) | KR20230029632A (https=) |
| CN (1) | CN116157135A (https=) |
| AU (1) | AU2021285907A1 (https=) |
| CA (1) | CA3180738A1 (https=) |
| MX (1) | MX2022015237A (https=) |
| WO (1) | WO2021247856A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021081244A1 (en) * | 2019-10-22 | 2021-04-29 | Fred Hutchinson Cancer Research Center | Base editor-mediated cd33 reduction to selectively protect therapeutic cells |
| CA3232593A1 (en) * | 2021-09-14 | 2023-03-23 | Vor Biopharma Inc. | Compositions and methods for multiplex base editing in hematopoietic cells |
| CA3236152A1 (en) * | 2021-11-09 | 2023-05-19 | Vor Biopharma Inc. | Compositions and methods for erm2 modification |
| CN120265314A (zh) * | 2022-09-28 | 2025-07-04 | 瑞泽恩制药公司 | 抗体抗性修饰受体以增强基于细胞的疗法 |
| CN116850210B (zh) * | 2023-01-17 | 2024-05-31 | 武汉大学 | 用于治疗急性髓系白血病的成分和方法 |
| WO2025030010A1 (en) * | 2023-08-01 | 2025-02-06 | Vor Biopharma Inc. | Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108290939B (zh) * | 2015-10-16 | 2023-01-13 | 纽约市哥伦比亚大学理事会 | 用于抑制谱系特异性抗原的组合物和方法 |
| JP2020523365A (ja) * | 2017-06-14 | 2020-08-06 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｒｎａスプライシングを改変する方法 |
| US11718659B2 (en) * | 2017-08-28 | 2023-08-08 | The Trustees Of Columbia University In The City Of New York | CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents |
| CA3110837A1 (en) * | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| WO2021081244A1 (en) * | 2019-10-22 | 2021-04-29 | Fred Hutchinson Cancer Research Center | Base editor-mediated cd33 reduction to selectively protect therapeutic cells |
-
2021
- 2021-06-03 CN CN202180060702.7A patent/CN116157135A/zh active Pending
- 2021-06-03 KR KR1020227043770A patent/KR20230029632A/ko active Pending
- 2021-06-03 CA CA3180738A patent/CA3180738A1/en active Pending
- 2021-06-03 WO PCT/US2021/035691 patent/WO2021247856A2/en not_active Ceased
- 2021-06-03 EP EP21817226.0A patent/EP4161535A4/en active Pending
- 2021-06-03 MX MX2022015237A patent/MX2022015237A/es unknown
- 2021-06-03 AU AU2021285907A patent/AU2021285907A1/en active Pending
- 2021-06-03 US US17/928,674 patent/US20240041923A1/en active Pending
- 2021-06-03 JP JP2022574196A patent/JP2023528415A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024105479A5 (https=) | ||
| AU2017355218B2 (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| Hudecek et al. | Non-viral therapeutic cell engineering with the Sleeping Beauty transposon system | |
| Muul et al. | Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial | |
| AU2016276702B2 (en) | CRISPR/CAS-related methods and compositions for improving transplantation | |
| Mac Donald et al. | KLRC1 knockout overcomes HLA-E-mediated inhibition and improves NK cell antitumor activity against solid tumors | |
| US20220257796A1 (en) | Recombinant ad35 vectors and related gene therapy improvements | |
| US20190136230A1 (en) | Genetically engineered cells and methods of making the same | |
| Tomuleasa et al. | Chimeric antigen receptor T-cells for the treatment of B-cell acute lymphoblastic leukemia | |
| US12398402B2 (en) | Reducing CD33 expression to selectively protect therapeutic cells | |
| US20220380776A1 (en) | Base editor-mediated cd33 reduction to selectively protect therapeutic cells | |
| JPWO2020150478A5 (https=) | ||
| JPWO2021247856A5 (https=) | ||
| EP4534680A1 (en) | Polynucleotide | |
| JP2023521410A (ja) | 大型のアデノウイルスペイロードの組み込み | |
| Trivedi et al. | Engineering B cells to treat and study human disease | |
| Caldwell et al. | Co-expression of full-length and truncated Ig mu-chains in human B lymphocytes results from alternative splicing of a single primary RNA transcript | |
| Caforio et al. | AATF/Che-1 RNA polymerase II binding protein overexpression reduces the anti-tumor NK-cell cytotoxicity through activating receptors modulation | |
| EP4450614A1 (en) | Treatment of leukemia by combining a hypomethylating agent in combination with engineered car-nk cells | |
| US20250369020A1 (en) | Production and/or delivery of multispecific binding agents | |
| Pedrazzani | MOBILIZATION-BASED CHEMOTHERAPY-FREE ENGRAFTMENT OF GENE EDITED HEMATOPOIETIC STEM CELLS | |
| RU2793803C2 (ru) | Иммунологически отличимые варианты поверхности клеток для применения в клеточной терапии | |
| WO2024173592A1 (en) | Modified stem cell compositions and methods for use | |
| WO2024238832A2 (en) | Pro-inflammatory cytokine enhanced steap1 recombinant receptors | |
| JP2024526851A (ja) | モノカルボン酸トランスポーター１１の阻害によるがんの細胞治療 |